In a commentary for APM's Marketplace, Dr. Stefan Kertesz questions the current process of approving new drugs, especially when researchers who set health care guidelines also have financial interests in pharmaceutical companies. He cites the timing of the National Cholesterol Education Panel's announcement on recommended cholesterol levels and the drug Vytorin's release to illustrate the need for reform.
Get drug firms out of drug approval
Jan 15, 2008
Add new comment